Find clear answers to common questions about Bergamonte®, including its botanical source, standardized polyphenol profile, clinical research, formulation applications, recommended use, certifications, and technical support.
The bergamot used in the Bergamonte® platform is sourced from Calabria in Southern Italy, a region historically associated with commercial cultivation of Citrus bergamia.
For formulators, Calabria represents more than a marketing origin. Geographic sourcing contributes to botanical provenance, traceability and consistency before extraction and standardization begin. Climate, soil, fruit maturity and harvest conditions can all influence botanical composition, making documented sourcing an important part of ingredient identity.
BPF® stands for Bergamot Polyphenolic Fraction. It is a standardized fraction derived from authentic Citrus bergamia and developed to concentrate and characterize the polyphenolic compounds naturally present in bergamot.
Unlike the broad term “bergamot extract,” BPF® refers to a defined ingredient platform characterized by botanical identity, Calabrian sourcing and a standardized flavanone profile.
Generic bergamot extracts may be described by an extraction ratio, a total-polyphenol number or another broad specification.
BPF® goes further by identifying and quantifying the characteristic flavanones associated with authentic bergamot. This matters because two ingredients sold under the same common botanical name are not necessarily compositionally equivalent or interchangeable with the ingredient used in published clinical research.
The five principal flavanones are:
Together, these compounds create the characteristic five-flavanone fingerprint used to characterize the BPF® platform.
Melitidin and brutieridin are characteristic bergamot flavanone derivatives that help distinguish authentic Citrus bergamia from other citrus materials.
They have also attracted scientific interest because of structural characteristics relevant to pathways involved in cholesterol metabolism. BPF®, however, is a multi-component polyphenolic fraction, so its research should not be reduced to these two compounds alone.
Polyphenols are a broad family of plant compounds. Flavanones are one class within that larger family.
For example, an ingredient may contain approximately 70% total polyphenols while separately being standardized to 38% combined principal flavanones. Those numbers describe different aspects of the ingredient.
For formulators, both measurements are useful: total polyphenols describe the broader phenolic fraction, while flavanone standardization provides greater detail about the characteristic bergamot compounds present.
Because total polyphenol content is a quantitative measurement, not a complete identity test.
Two extracts can report similar total-polyphenol percentages while containing different individual compounds. A more complete evaluation should consider botanical species, origin, the five-flavanone profile, analytical methodology, product specifications and the lot-specific Certificate of Analysis.
Bergamonte® Full Spectrum BPE-Complex® is a bergamot formulation built around the characteristic BPF® flavanone profile together with a broader matrix that includes pectin and vitamin C.
Unlike the individual BPF® concentration grades, Full Spectrum has dedicated human research examining healthy weight and multiple metabolic parameters within the same clinical protocol.
All four belong to the BPF® platform but provide different concentrations of the characteristic bergamot flavanone fraction.
Ingredient | Combined Flavanones | General Role |
BPF® 20 | ≥20% | Lower-concentration BPF® option |
BPF® 30 | 30% | Moderate standardized grade |
BPF® 38 | 38% | Higher-concentration/core clinical BPF® grade |
BPF Gold® | 47% | Highest-concentration BPF® grade |
Higher concentration is not automatically “better.” The appropriate grade depends on daily dosage, active target, serving size, formulation space, commercial objectives and the particular research being referenced.
No. They share the same underlying BPF® platform, botanical identity and characteristic flavanone profile, but they should be considered different standardized grades, not automatically interchangeable concentrations of one powder.
Clinical substantiation should remain connected to the specific preparation, dosage and protocol used in each published study whenever those details are available.
Not necessarily.
A higher standardization provides more flavanones per gram, which can be valuable when serving size or ingredient space is limited. A lower-concentration grade may offer advantages in other formulas where ingredient loading, cost or formulation flexibility are more important.
Ingredient selection should therefore begin with the finished-product objective rather than simply choosing the largest percentage available.
The best option depends on the intended positioning and formulation requirements.
Broadly, the portfolio includes options for healthy cholesterol and cardiometabolic formulas, healthy weight and metabolic wellness, vascular and sports-nutrition applications, liver-health formulations, nitric oxide support and bergamot-fiber applications.
Because research and specifications differ across the portfolio, formulators should use the individual ingredient pages and technical FAQs to match the commercial ingredient as closely as possible to the desired research, dose and application.
Botanical research is ingredient-specific.
A study performed with one BPF® concentration, BPE-Complex®, BPF Gold®, N.O.Max®, CitruSlim® or a Bergacyn® research formulation should not automatically be attributed to another ingredient simply because both contain bergamot.
The strongest substantiation comes from matching the botanical, standardization, composition and dosage as closely as possible to the material used in the published research.
The Bergamonte® platform has a substantial published human research program, but the current source documents contain different study-count totals.
Rather than relying solely on a headline number, product developers should review the Clinical Studies Library for the study design, population, duration, dosage, exact ingredient, standardization, endpoints and limitations of each publication.
Bergamot polyphenol research has evaluated measurements including total cholesterol, LDL-C, HDL-C, triglycerides and, in certain studies, more detailed lipoprotein particle characteristics.
This broader research is one reason the BPF® platform is frequently considered for formulations centered on healthy cholesterol and cardiometabolic wellness.
Bergamot polyphenol research has evaluated measurements including total cholesterol, LDL-C, HDL-C, triglycerides and, in certain studies, more detailed lipoprotein particle characteristics.
This broader research is one reason the BPF® platform is frequently considered for formulations centered on healthy cholesterol and cardiometabolic wellness.
Yes. Human research within the BPF® program has examined lipoprotein particle concentration and distribution, including small LDL particles.
These measurements provide additional context beyond conventional LDL-C and HDL-C values and are covered in greater detail within the relevant ingredient and clinical-study pages.
Yes. Published research has evaluated fasting glucose, insulin sensitivity and related metabolic measures in several BPF® and bergamot-containing protocols.
Results should be interpreted according to the individual ingredient, population and study design rather than generalized to every bergamot extract.
Yes. Dedicated research on the pectin-enriched Bergamonte® BPE-Complex® formulation has evaluated body weight and BMI alongside glucose, lipid and metabolic measurements.
The broader portfolio also includes finished formulations developed specifically around healthy weight and metabolic wellness, each with its own research context.
Yes. Bergamot-containing research has evaluated liver-related metabolic parameters as well as lipid, glucose, oxidative and inflammatory markers.
The Bergacyn® platform extends this area by combining bergamot with Cynara cardunculus, while certain research formulations also incorporate bergamot albedo fiber.
Yes. Human studies within the broader platform have investigated endothelial-dependent vascular responsiveness, nitric oxide availability and related vascular measurements.
Yes. Published research has evaluated nitric oxide, endothelial responsiveness, maximal oxygen uptake and other exercise-physiology measurements in trained participants.
There is emerging human research involving cognitive outcomes within specific study populations.
A robust evaluation should include several layers:
This provides substantially more assurance than relying only on a common botanical name or total-polyphenol percentage.
The BPF® platform uses analytical characterization of the individual bergamot flavanones rather than relying solely on a general total-polyphenol measurement.
Chromatographic techniques such as HPLC provide a more detailed phytochemical fingerprint and help confirm the presence and concentration of characteristic bergamot constituents.
The BPF® platform is derived from Citrus bergamia, which is distinct from Citrus aurantium, or bitter orange.
The source materials specifically distinguish the two botanicals and do not identify synephrine as a characteristic BPF® constituent. This botanical distinction is one reason accurate species identification is important.
Yes. BPF® ingredients can be incorporated into conventional oral dietary-supplement formats and multi-ingredient formulations.
However, physical properties such as solubility, particle size, density, flavor and recommended inclusion level vary by ingredient. Formulators should review the current specification for the specific BPF® grade rather than assuming identical performance across the portfolio.
There is no single solubility specification that should be applied to every ingredient in the Bergamonte® portfolio.
Solubility and dispersibility vary by grade and formulation. Product developers should refer to the current technical specification for the exact commercial ingredient being evaluated.
Bergamot-derived ingredients can have characteristic citrus and bitter sensory notes.
The degree to which flavor masking is necessary will depend on ingredient concentration, serving size and finished format. This is particularly relevant for powders, beverages, sachets and other formats in which the ingredient is tasted directly.
Published human studies have generally reported good tolerability over the durations investigated.
Safety considerations should nevertheless be evaluated for the specific ingredient, dose, intended population and finished formulation. Product developers should review the current safety documentation rather than extrapolating from one clinical protocol to every use.
Some published research has evaluated BPF® in protocols involving statin therapy.
That research does not establish universal compatibility with all medications or individuals. Finished-product companies should avoid making broad medication-interaction claims, and consumers taking prescription medications should consult an appropriate healthcare professional.
Bergamonte® has achieved an Independent Conclusion of GRAS for its intended food uses.
The preferred wording is:
“Bergamonte® has achieved an Independent Conclusion of GRAS for its intended uses in food.”
It should not be described as “FDA approved.” Companies requiring the specific conditions of use or supporting documentation should request the current GRAS materials from HP Ingredients.
The published research can provide substantiation relevant to appropriately worded structure-function positioning.
However, permissible claims depend on the exact ingredient, research, formulation, dosage, market and finished-product context. Regulatory review should therefore be performed on the specific claims intended for the finished product rather than assuming that every study endpoint can be translated directly into consumer-facing language.
Depending on the ingredient and customer requirement, documentation may include:
The available package should be confirmed for the individual ingredient.
Price per kilogram should not be the only comparison.
A more meaningful supplier evaluation should consider:
Botanical authenticity + geographic sourcing + flavanone standardization + analytical verification + clinical identity + quality documentation + technical support.
Those factors help determine whether two materials carrying the name “bergamot extract” are actually comparable.
Qualified formulators, manufacturers and finished-product companies can contact HP Ingredients for commercial ingredient information, technical documentation, clinical resources, formulation guidance and R&D samples.
let’s get started
Discuss your formulation goals, intended positioning, research needs, and product-development opportunities with the HP Ingredients team.
Schedule Now
Evaluate Bergamonte® for your next product concept with a sample for formulation, compatibility, and product-development testing.
Request Now
Ready to explore how Bergamonte® can support your product pipeline? Contact HP Ingredients for samples, technical documentation, clinical research, formulation guidance, and next-step support.
Contact Us